Latest Interferon beta-1a Stories
A drug developed for patients with leukemia also appears to regenerate brain cells and reverse the effects of relapsing-remitting multiple sclerosis, British researchers said on Wednesday.
Genzyme and Bayer have reported Phase II study results demonstrating the potential of alemtuzumab in treatment-naive MS patients.
By Rita Rubin A leukemia drug was about 70% more effective than a standard therapy in treating early multiple sclerosis, according to clinical trial results in today's New England Journal of Medicine.
Genzyme Corporation (Nasdaq: GENZ) and Bayer HealthCare Pharmaceuticals Inc.
Merck Serono, a division of Merck KGaA, Darmstadt, Germany, has announced that the ongoing Improve study met its primary endpoint.
Biogen Idec (NASDAQ: BIIB) today announced that data was presented from the ASSURANCE (ASSessment of Drug Utilization, EaRly TreAtmeNt, and Clinical OutcomEs) study, showing the long-term benefits of AVONEX(R) (interferon beta-1a IM) therapy in patients with relapsing multiple sclerosis (MS) for up to 15 years.
Biogen Idec (NASDAQ: BIIB) will present new data on the company's leading multiple sclerosis (MS) franchise at the World Congress on Treatment and Research in Multiple Sclerosis taking place this week in Montreal, Canada.
Merck KGaA has announced that its Merck Serono division has completed patient enrollment in the Reflex trial of Rebif in patients at risk of developing multiple sclerosis.
Bayer HealthCare Pharmaceuticals Inc.
Biogen Idec has completed enrollment in the Assurance trial, a long-term follow-up study which will assess up to 15 years of Avonex treatment in an effort to provide detailed data on the long-term efficacy of the drug.